Martin Ebon

About

Martin Ebon is a leading urologic surgeon and researcher whose work is reshaping the surgical management of bladder cancer. His primary research focuses on robotic-assisted radical cystectomy, with a specific emphasis on comparing outcomes and cost-effectiveness against traditional open surgery. Ebon’s landmark 2022 study, cited over 320 times, provided pivotal evidence that robot-assisted radical cystectomy with intracorporeal urinary diversion does not significantly reduce 90-day morbidity or mortality compared to open surgery, challenging prevailing assumptions and guiding clinical practice. He further advanced the field with a 2023 cost-effectiveness analysis, demonstrating the economic implications of robotic techniques for healthcare systems. Ebon also investigates the physiological impact of surgery, including a study on how different pneumoperitoneum pressures affect inflammatory markers and postoperative ileus. His work has been instrumental in defining the evidence base for robotic cystectomy, influencing surgical protocols and patient counseling worldwide. Through rigorous comparative effectiveness research, Ebon continues to drive the evolution of bladder cancer surgery toward more efficient, evidence-based, and patient-centered care.

Research Focus

Key Achievements

Top Papers

1. 1
   Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer

   320 citations · 2022
2. 2
   Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer

   26 citations · 2023
3. 3
   Comparing different pneumoperitoneum (12 vs. 15 mmHg) pressures with cytokine analysis to evaluate clinical outcomes in patients undergoing robotic‐assisted laparoscopic radical cystectomy and intracorporeal robotic urinary diversion

   4 citations · 2023

Key Collaborators

Contact & Links